ABL Tyrosine Kinase Inhibitors Linked to Arterial Thrombosis – Blood Journals Portfolio
Blood Journals Portfolio shared a post on LinkedIn about a recent article by Richard Travers et al, published in Blood VTH:
”Another important study in observance of Deep Vein Thrombosis Awareness Month, focusing on Arterial Thrombosis.
‘Distinct endothelial cell toxicities of Abl tyrosine kinase inhibitors lead to arterial thrombosis’ published on January 7, 2026, concluded that Dasatinib, ponatinib, and nilotinib damage ECs in different ways, all of which can contribute to arterial thrombosis.”
Title: Distinct endothelial cell toxicities of Abl tyrosine kinase inhibitors lead to arterial thrombosis
Authors: Richard Travers, Alec Stepanian, Sebastiana Redford, Gregory Martin, Nicole L. Svedberg, Kun Xu, Glenn Merrill-Skoloff, Christopher Chen, Robert Flaumenhaft, Iris Z. Jaffe
Read the Full Article on Blood VTH
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 20, 2026, 12:14Yanki Yarman: Linking Genetic Variants to Clinical Outcomes in Thrombosis
-
Apr 20, 2026, 12:09Syed Sibtain Raza: White Blood Cells – Understanding Morphology for Better Diagnosis
-
Apr 20, 2026, 11:23Bastu Odoka: Jehovah’s Witness News on Transfusion… and a Question Worth Asking
-
Apr 20, 2026, 11:15William Aird: A Physiological Approach to Anemia
-
Apr 20, 2026, 10:59Eric Topol: Is the Interferon Pathway a Key Driver of Inflammaging and Aging
-
Apr 20, 2026, 10:47Emmanuel J Favaloro: Emerging Perspectives on Extracellular Vesicles in Hemophilia
-
Apr 20, 2026, 10:21Pierpaolo Di Micco: Honored to Join the ESVM Congress in Lausanne
-
Apr 20, 2026, 08:17Heghine Khachatryan: Key Takeaways from Day 1 – WFH 2026 World Congress
-
Apr 20, 2026, 08:10Justin Nelson-Deering։ Celebrating World Hemophilia Day in Pediatric Care